Last reviewed · How we verify
NCT05734599
NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis
trial testing NMR-based metabolic profiling in Metabolic Dysfunction-associated Fatty Liver Disease in 1,194 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Huazhong University of Science and Technology |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,194 |
| Start date | 1 March 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- NMR-based metabolic profiling
Conditions studied
- Metabolic Dysfunction-associated Fatty Liver Disease — all drugs for Metabolic Dysfunction-associated Fatty Liver Disease →
- Metabolic Disease — all drugs for Metabolic Disease →
Sponsor
Huazhong University of Science and Technology
Who can join
18 and older, any sex, with Metabolic Dysfunction-associated Fatty Liver Disease or Metabolic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aim to find out metabolic molecules in blood and urine which could identify high risk of advanced fibrosis in MAFLD patients via NMR-based metabolic profiling.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05734599
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Dysfunction-associated Fatty Liver Disease
Currently open trials in the same condition.
- NCT05974904 — Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study · recruiting
- NCT06541132 — Positive Association of US-FLI With the Severity of CAD · recruiting
Other Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
- NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
- NCT07509866 — Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal · NA · recruiting
- NCT07326943 — Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block · NA · recruiting
- NCT07229976 — Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05734599 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huazhong University of Science and Technology
- Last refreshed: 21 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734599.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing